Loading...
•
Sep 30, 2021
Eton Q3 2021 Earnings Report
Eton Pharmaceuticals reported financial results with revenue of $0.8 million and a net loss of $6.1 million.
Key Takeaways
Eton Pharmaceuticals reported third quarter financial results with revenue of $0.8 million and a net loss of $6.1 million. The company made advancements to its commercial portfolio with two more FDA-approved products and is increasing ALKINDI SPRINKLE’s commercial footprint.
Eton gained two more FDA-approved products, EPRONTIA and carglumic acid.
Eton is increasing ALKINDI SPRINKLE’s commercial footprint through a co-promotion arrangement with Tolmar Pharmaceuticals.
Eton now has six FDA-approved products, three of which (carglumic acid, EPRONTIA®, and Rezipres®) are expected to launch in the fourth quarter of 2021.
Eton reported revenue of $0.8 million for the third quarter of 2021.
Forward Guidance
Eton is in an even stronger position to deliver significant revenue and reach sustained profitability in 2022.
Positive Outlook
- Eton gained two more FDA-approved products, EPRONTIA and carglumic acid.
- EPRONTIA should launch in the fourth quarter.
- carglumic acid should launch in the fourth quarter.
- Eton is increasing ALKINDI SPRINKLE’s commercial footprint more than ten-fold through an attractive co-promotion arrangement with Tolmar Pharmaceuticals.
- Eton now has six FDA-approved products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...